AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10637702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreatoduodenectomy (PPPD)
Number of subjects: 48
Study 10637702 — intervention group
Group type: COMPARATOR
Intervention: Duodenopancreatectomy (PD)
Number of subjects: 48
Study 7737776 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 3 months
Number of subjects: 53
Study 7737776 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine 250 mg for 3 months
Number of subjects: 53
Study 2044924 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 18
Study 2044924 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1N hydrochloric acid infusion
Number of subjects: 18
Study 2044924 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous duodenal secretions infusion
Number of subjects: 18
Study 2044924 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to acid and/or bile
Number of subjects: 18
Study 2044924 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative response group
Number of subjects: 18
Study 6291739 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily radiotherapy (5000 rad in 25 fractions in 5 weeks)
Number of subjects: 157
Study 6291739 — intervention group
Group type: COMPARATOR
Intervention: Q3h Cobalt 60 irradiation (3600‐4000 rad in 36‐40 fractions of 100 rad each, given 4 fractions per day at 3‐hour intervals over two weeks)
Number of subjects: 157
Study 6291739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (hyperfractionation and daily regimens)
Number of subjects: 157
Study 6291739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation with chemotherapy
Number of subjects: 157
Study 31305505 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal hyperreflective material (SHRM) with layered appearance
Number of subjects: 0
Study 31305505 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal hyperreflective material (SHRM) with hyperreflective spots
Number of subjects: 0
Study 31305505 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation between SHRM and outer retina
Number of subjects: 0
Study 31305505 — intervention group
Group type: EXPERIMENTAL
Intervention: Disappearance of SHRM
Number of subjects: 0
Study 31305505 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered appearance of SHRM at baseline
Number of subjects: 0
Study 31305505 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing reflectivity of SHRM lesion
Number of subjects: 0
Study 31305505 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased width and area of baseline SHRM at the foveal center
Number of subjects: 0
Study 30936690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate altitude exposure (2,590 m)
Number of subjects: 37
Study 28296779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh packed red blood cells (RBCs) stored less than 10 days
Number of subjects: 0
Study 28296779 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-storage packed red blood cells (RBCs) stored more than 10 days but less than 35 days
Number of subjects: 0
Study 28296779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transfusion)
Number of subjects: 0
Study 25616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 0
Study 25616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (in patients with prior cytokine-containing regimen)
Number of subjects: 0
Study 25616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (in patients with prior sunitinib treatment)
Number of subjects: 0
Study 25453119 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib plus phloroglucinol
Number of subjects: 236
Study 25453119 — intervention group
Group type: COMPARATOR
Intervention: Parecoxib plus placebo
Number of subjects: 236
Study 21111681 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 125
Study 21111681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 125
Study 21111681 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 125
Study 21111681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate
Number of subjects: 125
Study 21111681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine
Number of subjects: 125
Study 19608833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (end-tidal 1.5%-2%)
Number of subjects: 120
Study 19608833 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia (end-tidal 6%-7%)
Number of subjects: 120
Study 19608833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 17372669 — intervention group
Group type: EXPERIMENTAL
Intervention: Components Separation Technique (CST)
Number of subjects: 39
Study 17372669 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic Repair (PR)
Number of subjects: 39
Study 15964483 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine at 10 microg
Number of subjects: 2
Study 15964483 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine at 25 microg
Number of subjects: 2
Study 15964483 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine at 50 microg
Number of subjects: 2
Study 11796658 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (Cr, 4 x 5 g/day, 4 days)
Number of subjects: 10
Study 11796658 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (Caf, 5 mg x kg(‐1) x day(‐1), 3 days)
Number of subjects: 10
Study 11796658 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine + Caffeine supplementation (Cr+Caf)
Number of subjects: 10
Study 11796658 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute caffeine intake (ACaf, 5 mg/kg)
Number of subjects: 10
Study 11796658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10752310 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold transcranial magnetic stimulation (TMS)
Number of subjects: 7
Study 10752310 — intervention group
Group type: COMPARATOR
Intervention: Control (no TMS)
Number of subjects: 7
Study 8648453 — intervention group
Group type: EXPERIMENTAL
Intervention: Earmuffs reducing noise intensity by 7 to 12 dB
Number of subjects: 30
Study 8648453 — intervention group
Group type: COMPARATOR
Intervention: Usual noise in the NICU
Number of subjects: 30
Study 2404843 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin administered at 06.00
Number of subjects: 0
Study 2404843 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin administered at 18.00
Number of subjects: 0
Study 7298477 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies (specific types not detailed)
Number of subjects: 264
Study 7298477 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 264
Study 7298477 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation
Number of subjects: 264
Study 7298477 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 264
Study 31197861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 61
Study 31197861 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate (FeSulf)
Number of subjects: 61
Study 28982527 — intervention group
Group type: EXPERIMENTAL
Intervention: Text4baby and Quit4baby (intervention)
Number of subjects: 497
Study 28982527 — intervention group
Group type: COMPARATOR
Intervention: Text4baby (control)
Number of subjects: 497
Study 25946691 — intervention group
Group type: COMPARATOR
Intervention: Classic inverted ILM flap technique
Number of subjects: 87
Study 25946691 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal inverted ILM flap technique
Number of subjects: 87
Study 22633446 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-fortified milk (SM 20% of all phospholipids in milk)
Number of subjects: 24
Study 22633446 — intervention group
Group type: COMPARATOR
Intervention: Control group (SM 13% of all phospholipids in milk)
Number of subjects: 24
Study 21640762 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg per day (AT group, n=52)
Number of subjects: 104
Study 21640762 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LM group, n=52)
Number of subjects: 104
Study 21640762 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC group, n=40)
Number of subjects: 104
Study 20001838 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique (NET) - two 30-minute sessions approximately 2 weeks apart
Number of subjects: 15
Study 20001838 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 15
Study 17195236 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT-192 (10 mg/kg)
Number of subjects: 45
Study 17195236 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT-192 (5 mg/kg)
Number of subjects: 45
Study 17195236 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT-192 (0.5 mg/kg)
Number of subjects: 45
Study 17195236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17195236 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT-192 (all doses)
Number of subjects: 45
Study 12686786 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/h nimodipine
Number of subjects: 295
Study 12686786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/h nimodipine
Number of subjects: 295
Study 12686786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 12686786 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nimodipine
Number of subjects: 295
Study 12686786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine treatment
Number of subjects: 295
Study 12686786 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP reduction
Number of subjects: 295
Study 12686786 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP reduction
Number of subjects: 295
Study 10985616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (LHRH antagonist)
Number of subjects: 273
Study 10985616 — intervention group
Group type: COMPARATOR
Intervention: Buserelin (LHRH agonist)
Number of subjects: 273
Study 9368162 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% eyedrops
Number of subjects: 281
Study 9368162 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (brief course of steroids)
Number of subjects: 281
Study 1547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.036 mg kg‐1
Number of subjects: 31
Study 1547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.071 mg kg‐1
Number of subjects: 31
Study 1547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.43 mg kg‐1
Number of subjects: 31
Study 3904908 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylstilboestrol 3 mg/day
Number of subjects: 140
Study 3904908 — intervention group
Group type: COMPARATOR
Intervention: estramustine 560 mg/day
Number of subjects: 140
Study 31779993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassia alata Linn tea
Number of subjects: 90
Study 31779993 — intervention group
Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 90
Study 29452901 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (25 Gy in five fractions)
Number of subjects: 0
Study 29452901 — intervention group
Group type: COMPARATOR
Intervention: Commonly used radiotherapy (40 Gy in 15 fractions)
Number of subjects: 0
Study 27831636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of dust mite drops, once per day, gradually increasing the dose to reach a high maintenance level.
Number of subjects: 156
Study 27831636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of dust mite drops
Number of subjects: 156
Study 24004349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplements (800 IU/day)
Number of subjects: 164
Study 24004349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 22541754 — intervention group
Group type: COMPARATOR
Intervention: PF-00734200 10 mg single dose
Number of subjects: 16
Study 22541754 — intervention group
Group type: COMPARATOR
Intervention: PF-00734200 100 mg single dose
Number of subjects: 16
Study 22541754 — intervention group
Group type: COMPARATOR
Intervention: PF-00734200 20 mg once daily for 6 days
Number of subjects: 16
Study 22541754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20565159 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific smoking messages
Number of subjects: 243
Study 20565159 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking messages
Number of subjects: 243
Study 20565159 — intervention group
Group type: COMPARATOR
Intervention: Culturally specific exercise/weight messages
Number of subjects: 243
Study 20565159 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise/weight messages
Number of subjects: 243
Study 18384853 — intervention group
Group type: COMPARATOR
Intervention: Supportive telephone contact by a urology nurse (Control)
Number of subjects: 216
Study 18384853 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly postoperative pelvic floor muscle training (PFMT) (Treatment)
Number of subjects: 216
Study 15875528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg once daily
Number of subjects: 164
Study 15875528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg twice daily
Number of subjects: 164
Study 15875528 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 880 microg twice daily
Number of subjects: 164
Study 12740791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 32
Study 12740791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 32
Study 12740791 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 32
Study 10561630 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6 g loading dose in 100 mL isotonic sodium chloride solution, followed by 2 g/h infusion for 3 hours at 125 mL/h)
Number of subjects: 0
Study 10561630 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution (100 mL isotonic sodium chloride solution, similar infusion rate)
Number of subjects: 0
Study 9046544 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment using specially designed compression pads, elevation of the injured foot (24 h), repeated elastic wrapping, early full weight-bearing and proprioceptive range-of-motion training (Group I, n = 46)
Number of subjects: 86
Study 9046544 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with an elastic bandage, partial weight bearing and crutches until pain subsided (Group II, n = 40)
Number of subjects: 86
Study 9046544 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment (Group I)
Number of subjects: 86
Study 9046544 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Group II)
Number of subjects: 86
Study 1989755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium (2 mg/kg body weight iv)
Number of subjects: 52
Study 1989755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1989755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 52
Study 6340700 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol hydrochloride (Endak, Endak mite) for 4 weeks after a 7-day placebo period
Number of subjects: 40
Study 6340700 — intervention group
Group type: COMPARATOR
Intervention: pindolol (standard medication)
Number of subjects: 40
Study 30222818 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge pars plana incision with suture
Number of subjects: 22
Study 30222818 — intervention group
Group type: COMPARATOR
Intervention: 3.5-mm corneal incision with suture
Number of subjects: 22
Study 29441845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivy leaves cough liquid containing EA 575®
Number of subjects: 181
Study 29441845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 24819911 — intervention group
Group type: COMPARATOR
Intervention: Standard dose escalation scheme of dipyridamole
Number of subjects: 114
Study 24819911 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow dose escalation scheme of dipyridamole
Number of subjects: 114
Study 22802432 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 H1N1 vaccine and seasonal TIV (TIV; split virion)
Number of subjects: 531
Study 22802432 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 H1N1 vaccine
Number of subjects: 531
Study 22802432 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV
Number of subjects: 531
Study 19864172 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 16
Study 19864172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 18540726 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional Balance Scale administered via computerized and paper versions
Number of subjects: 2334
Study 18540726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical confirmatory factor analysis multi‐trait multi‐method approach (HCFA MTMM)
Number of subjects: 2334
Study 18540726 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional Balance for smoking in adolescence
Number of subjects: 2334
Study 15785936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen co-treatment
Number of subjects: 204
Study 15785936 — intervention group
Group type: COMPARATOR
Intervention: No ibuprofen co-treatment (Control)
Number of subjects: 204
Study 12017805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 0
Study 12017805 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 10426160 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally once a day for 4 days
Number of subjects: 9
Study 8775645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.5 g.kg‐1 body weight)
Number of subjects: 6
Study 8775645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium carbonate, 0.5 g.kg‐1 body weight)
Number of subjects: 6
Study 2207450 — intervention group
Group type: COMPARATOR
Intervention: CSP alone (n = 39)
Number of subjects: 76
Study 2207450 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP + MTX (n = 37)
Number of subjects: 76
Study 6105392 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (5 ng kg‐1 min‐1) during dialysis
Number of subjects: 0
Study 31679107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic lymphadenectomy (pLA)
Number of subjects: 0
Study 31211327 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Number of subjects: 0
Study 31211327 — intervention group
Group type: COMPARATOR
Intervention: Medical Therapy
Number of subjects: 0
Study 27865057 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA group
Number of subjects: 0
Study 27865057 — intervention group
Group type: COMPARATOR
Intervention: AGA group
Number of subjects: 0
Study 26356419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 179
Study 26356419 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 179
Study 26356419 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume control (proxy for ambulatory systolic blood pressure)
Number of subjects: 179
Study 26356419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for inferior vena cava diameter
Number of subjects: 179
Study 23330835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter chocolate
Number of subjects: 180
Study 23330835 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 180
Study 23330835 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 22235525 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype medication drawer (Drawer 2)
Number of subjects: 26
Study 22235525 — intervention group
Group type: COMPARATOR
Intervention: Baseline medication drawer (Drawer 1)
Number of subjects: 26
Study 19516186 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 23504
Study 19516186 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 23504
Study 19516186 — intervention group
Group type: COMPARATOR
Intervention: Calcium Channel Blockers (CCB)
Number of subjects: 23504
Study 17410045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2, day 1, every 3 weeks for eight cycles)
Number of subjects: 87
Study 17410045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 for cycles 1 and 2) followed by Gemcitabine (1200 mg/m2, days 1 and 8, every 3 weeks for cycles 3 and 4, repeated for a total of eight cycles)
Number of subjects: 87
Study 15482398 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 600
Study 15482398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 11535311 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatographically purified rabies vaccine (CPRV)
Number of subjects: 680
Study 11535311 — intervention group
Group type: COMPARATOR
Intervention: Human diploid cell vaccine (HDCV)
Number of subjects: 680
Study 10617953 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-reconstituted red wine (ARW)
Number of subjects: 9
Study 10617953 — intervention group
Group type: COMPARATOR
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 9
Study 9179581 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom availability program in high schools
Number of subjects: 9
Study 9179581 — intervention group
Group type: COMPARATOR
Intervention: Comparison schools (control group)
Number of subjects: 9
Study 1412141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 88
Study 1412141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 3931467 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide plus insulin
Number of subjects: 22
Study 3931467 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus insulin
Number of subjects: 22
Study 30834441 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (≥4 cups of total coffee/day)
Number of subjects: 22948